NCT00274287View on ClinicalTrials.gov

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

GM CSF

250 ug/m2 daily for 2 weeks followed by 2 weeks of rest

Trial Locations (1)

60068

Oncology Specialists, SC, Park Ridge

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Oncology Specialists, S.C.

OTHER

NCT00274287 - GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere | Biotech Hunter | Biotech Hunter